Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target
Open accessThe DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index; 53 of the 139 sources its claims cite were checked for support.
Abstract
Trimethylamine N-oxide (TMAO) is a molecule generated from choline, betaine, and carnitine via gut microbial metabolism. The plasma level of TMAO is determined by several factors including diet, gut microbial flora, drug administration and liver flavin monooxygenase activity. In humans, recent clinical studies evidence a positive correlation between elevated plasma levels of TMAO and an increased risk for major adverse cardiovascular events. A direct correlation between increased TMAO levels and neurological disorders has been also hypothesized. Several therapeutic strategies are being explored to reduce TMAO levels, including use of oral broad spectrum antibiotics, promoting the growth of bacteria that use TMAO as substrate and the development of target-specific molecules. Despite the accumulating evidence, it is questioned whether TMAO is the mediator of a bystander in the disease process. Thus, it is important to undertake studies to establish the role of TMAO in human health and disease. In this article, we reviewed dietary sources and metabolic pathways of TMAO, as well as screened the studies suggesting possible involvement of TMAO in the etiology of cardiovascular and neurological disorders, underlying the importance of TMAO mediating inflammatory processes. Finally, the potential utility of TMAO as therapeutic target is also analyzed.
Overview
CoChat Summary
TL;DR
TMAO is a gut-microbiota-derived metabolite of dietary choline, betaine, and carnitine that is oxidized hepatically by FMO3 and has been positively associated with cardiovascular events, neurological disorders, and inflammation. This narrative review concludes that TMAO may be a biomarker or therapeutic target, but causality remains unresolved because it may instead be a bystander.
Key findings
- TMAO is generated from choline, betaine, L-carnitine, γ-butyrobetaine, and ergothioneine via gut microbial TMA, then oxidized mainly by hepatic FMO3; FMO1 has tenfold lower specific activity in liver. Nearly 95% of TMA is oxidized and excreted in urine in a 3:95 TMA:TMAO ratio within 24 h, with only 4% excreted in feces and less than 1% in breath.
- Elevated plasma TMAO is positively correlated with increased risk for major adverse cardiovascular events, but the association is inconsistent: bariatric surgery raises TMAO despite reducing CVD risk, fish/seafood are rich in TMAO yet not linked to increased CVD risk, and FMO3 may influence atherosclerosis independently of TMAO.
- TMAO has been linked to neurological disorders in both harmful and protective directions: it can stabilize/modify amyloid beta aggregation and disrupt the blood-brain barrier, but as an osmolyte/chemical chaperone it can promote tau-tubulin assembly, inhibit PrPC-to-PrPSc conversion, reduce ataxin-3 aggregation, and favor compact α-synuclein forms.
- Inflammation is proposed as an underlying mechanism: TMAO is associated with TNF-α, IL-6, and C-reactive protein, and activates NLRP3 inflammasome via SIRT3-SOD2-mitochondrial ROS or ROS-TXNIP pathways; therapeutic strategies include antibiotics, pre/probiotics, methanogenic bacteria, DMB, meldonium, herbal products, resveratrol, and enalapril, though antibiotics suppress TMAO only until about one month after withdrawal.
Methods
- Narrative review of dietary sources and metabolic pathways of TMAO, plus screening of studies suggesting involvement in cardiovascular and neurological disorders, inflammation, and therapeutic strategies.
- Evidence base consists of cited human clinical/observational studies, animal models, and cell experiments; no new primary data are reported.
- Main analysis is qualitative synthesis, with referenced tables (Tables 1–5) organizing diet, CVD, neurological, inflammation, and therapeutic findings; no systematic search strategy or meta-analysis is described.
Limitations
- The paper states that the exact mechanism underlying the correlation between high plasma TMAO and atherosclerosis is still unknown, and it is questioned whether TMAO is a mediator or a bystander in disease.
- The paper states that human dietary TMAO metabolism is poorly understood and that the amount of TMA excreted in feces has not been carefully quantified.
- Evident from the text: this is a narrative review without systematic search or quantitative synthesis, and many conclusions rely on animal/cell studies or mixed human observational findings, so causality cannot be established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
24 Valid · 2 Not valid · 67 Not checked · 7 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In humans, recent clinical studies evidence a positive correlation between elevated plasma levels of TMAO and an increased risk for major adverse cardiovascular events.”
§ Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target > Abstract
What the sources say
- Supportedcites [7] Wang, 2011, Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease, Nature source
The Results section describes a human cohort in which plasma analytes associated with cardiac risk were identified by comparing patients who experienced myocardial infarction, stroke or death within three years with those who did not. The Methods define that outcome as major adverse cardiovascular events (MACE), and the Results identify TMAO as an analyte associated with CVD risk. The separate large clinical cohort also found a dose-dependent association between elevated TMAO and CVD, though that analysis concerned prevalent disease rather than incident events. (LLM, conf=0.91)
- Partly supportedcites [14] Koeth, 2013, Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis, Nat. Med. sourceExperimental — accuracy not yet measured
The Results section, “Plasma levels of L-carnitine are associated with CVD” (page not provided), reports that carnitine was associated with incident major adverse cardiac events only among subjects with high plasma TMAO. It interprets TMAO as the likely driver of the cardiovascular-risk association, but the quoted passage does not report a direct correlation between TMAO levels and event risk across humans generally. (LLM, conf=0.82)
- Supportedcites [52] Tang, 2013, Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk, N. Engl. J. Med. source
The Results (Clinical Outcomes) report a graded increase in major adverse cardiovascular event risk as plasma TMAO levels increased, including after adjustment for traditional risk factors. The Discussion explicitly describes this as a correlation between high plasma TMAO and increased risk of incident events. (LLM, conf=0.95)
- Supportedcites [53] Lever, M., George, P.M., Slow, S., Bellamy, D., Young, J.M., Ho, M., McEntyre, C.J., Elmslie, J.L., Atkinson, W., and Molyneux, S.L. (2014). Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational Study. PLoS ONE, 9. source
The Introduction reports that several studies found plasma TMAO predictive of cardiovascular events. The Results (Effect of diabetes on prediction of events) also associate elevated TMAO with cardiovascular outcomes in this human cohort, particularly among subjects with diabetes; the association was narrower among those without diabetes. (LLM, conf=0.90)
- Not checked yetcites [54] Mente, 2015, The Relationship Between Trimethylamine-N-Oxide and Prevalent Cardiovascular Disease in a Multiethnic Population Living in Canada, Can. J. Cardiol. source
- Partly supportedcites [55] Ueland, 2015, Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure, J. Intern. Med. sourceExperimental — accuracy not yet measured
The chronic-heart-failure survival results report that higher plasma TMAO was associated with more deaths or heart transplants over 5.2 years. That supports an association with an adverse outcome in this patient group, but the paper did not assess major adverse cardiovascular events broadly, and the survival association was no longer statistically significant after multivariable adjustment. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“nowadays there is convincing evidence suggesting an association between TMAO and inflammation [8,9,10,11,12]”
§ Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target > 1. Introduction
What the sources say
- Supportedcites [8] Chen, 2017, Gut Microbiota-Dependent Metabolite Trimethylamine N-Oxide Contributes to Cardiac Dysfunction in Western Diet-Induced Obese Mice, Front. Physiol. source
The paper clearly treats an association between TMAO and inflammation: the Discussion (Results/Discussion sections) states that 'elevated circulating TMAO levels in mice fed a WD induce cardiac inflammation probably by shifting the cytokine profile from anti- to pro-inflammatory cytokines,' with DMB (the TMA-formation inhibitor) reversing TNF-α, IL-1β and IL-10 changes, and the Conclusion attributes WD-induced cardiac inflammation to elevated circulating TMAO. The Introduction also notes elevated TMAO 'promote[s] vascular inflammation (Seldin et al., 2016).' The citing sentence is a broad, unqualified background statement offered among several pooled citations, and our copy supports it at that level; its own evidence is murine (Western-diet-induced obesity), which the claim does not qualify either way. (LLM, conf=0.82)
- Supportedcites [9] Chen, 2017, Trimethylamine-N-Oxide Induces Vascular Inflammation by Activating the NLRP3 Inflammasome Through the SIRT3-SOD2-mtROS Signaling Pathway, J. Am. Heart Assoc. source
The cited paper directly evidences a TMAO–inflammation link: Results ('TMAO Induced Inflammation in Endothelial Cells', p. ~5) show TMAO (600 μmol/L, 24 h) significantly raised IL-1β, ICAM-1 and MMP-9 and increased monocyte adhesion without affecting viability, and the following subsection shows MCC950/YVAD/siRNA against NLRP3 blocked these effects. The Discussion reinforces it, stating 'These results support a role for TMAO in the activation of inflammatory pathways in cells of the vasculature, leading to endothelial cell leukocyte recruitment and AS,' and noting TMAO induces cytokines/adhesion molecules via NF-κB in endothelial and smooth muscle cells in vivo and in vitro. The hedged claim of 'convincing evidence for an association' is thus stated by this source with equal or greater confidence (indeed as a causal mechanism). (LLM, conf=0.90)
- Partly supportedcites [10] Rohrmann, 2016, Plasma Concentrations of Trimethylamine-N-oxide Are Directly Associated with Dairy Food Consumption and Low-Grade Inflammation in a German Adult Population, J. Nutr. sourceExperimental — accuracy not yet measured
Rohrmann et al. (2016) do report an association between TMAO and inflammation — the Abstract Conclusions state 'plasma TMAO concentrations were positively associated with inflammation' and the Results (Table 4) show higher TNF-a, sTNF-R p55 and sTNF-R p75 in the top TMAO quartile of 271 German adults, though with no differences in CRP or IL-6. What our copy does not support is the strength/consistency implied by 'convincing evidence': the Discussion notes that prior studies of TMAO and inflammatory markers (mostly CRP) were conducted almost entirely in participants with heart or kidney disease and that one reported an inverse association with CRP, and it explicitly states 'From the current evidence it is yet unclear if and how TMAO and the pathway leading to TMAO formation are causally linked to inflammation in general'. The overstatement is the 'convincing' characterisation of a cross-sectional, single-population, marker-inconsistent association. (LLM, conf=0.75)
- Not checked yetcites [11] Sun, 2016, Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome, Biochem. Biophys. Res. Commun. source
- Not checked yetcites [12] Yue, 2017, Trimethylamine N-oxide prime NLRP3 inflammasome via inhibiting ATG16L1-induced autophagy in colonic epithelial cells, Biochem. Biophys. Res. Commun. source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Carnitine oxidoreductase is the main enzyme responsible for the conversion of L-carnitine into TMA [20]”
§ Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target > 1. Introduction > 1.1. TMAO Metabolism
What the sources say
- Partly supportedcites [20] Zhu, 2014, Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The Heterologous Expression section reports that CntA and CntB are necessary and sufficient for carnitine-to-TMA conversion in the tested system. The paper calls them an oxygenase and a reductase, not “carnitine oxidoreductase,” and does not establish that they are the main enzyme responsible for this conversion generally. Page numbers are unavailable in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“studies suggesting an association between high plasma TMAO levels and risk for developing atherosclerosis have increased markedly [7,13,14,15,16,17]”
§ Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target > 1. Introduction
What the sources say
- Supportedcites [7] Wang, 2011, Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease, Nature source
The Results section reports a dose-response relationship between plasma TMAO and atherosclerotic plaque burden in people undergoing coronary angiography. It also reports a positive correlation between plasma TMAO and plaque size in mice, supporting the citing sentence’s hedged association claim. (LLM, conf=0.91)
- Not checked yetcites [13] Geng, 2018, Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway, Biomed. Pharmacother. source
- Partly supportedcites [14] Koeth, 2013, Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis, Nat. Med. sourceExperimental — accuracy not yet measured
The Results section on plasma L-carnitine and CVD reports that cardiovascular-event risk was associated with carnitine only among people with high plasma TMAO, and says the findings are consistent with TMAO driving the cardiovascular-risk association. The Discussion describes pro-atherosclerotic effects of TMAO. Neither passage establishes that high plasma TMAO predicts the development of atherosclerosis specifically, rather than cardiovascular events or atherosclerosis-related mechanisms; page numbers are unavailable in our copy. (LLM, conf=0.82)
- Supportedcites [15] Koeth, 2014, γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO, Cell Metab. source
The Introduction reports that plasma TMAO levels are independently associated with cardiovascular risk and links TMAO production to the development of atherosclerosis. The Discussion adds that mice with the highest plasma TMAO had the most aortic-root plaque, while noting that causation in humans remains unproven. The citing sentence claims an association, not causation. (LLM, conf=0.90)
- Not checked yetcites [16] Mohammadi, 2016, Trimethylamine-N-Oxide Treatment Induces Changes in the ATP-Binding Cassette Transporter A1 and Scavenger Receptor A1 in Murine Macrophage J774A.1 cells, Inflammation source
- Supportedcites [17] Wang, 2015, Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis, Cell source
The Introduction (page unavailable) says blood TMAO levels are associated with prevalent atherosclerotic heart disease and incident major adverse cardiac events. It also reports that TMAO accelerates atherosclerosis in animal models, supporting the citing sentence’s hedged association while distinguishing the animal and clinical evidence. (LLM, conf=0.87)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Some studies have demonstrated that people after bariatric surgery show short- and long-term higher plasma TMAO levels.”
§ Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target > 3. Relationship between Atherosclerosis, Cardiovascular Disease and TMAO
What the sources say
- Partly supportedcites [65] Narath, S.H., Mautner, S.I., Svehlikova, E., Schultes, B., Pieber, T.R., Sinner, F.M., Gander, E., Libiseller, G., Schimek, M.G., and Sourij, H. (2016). An Untargeted Metabolomics Approach to Characterize Short-Term and Long-Term Metabolic Changes after Bariatric Surgery. PLoS ONE, 11. sourceExperimental — accuracy not yet measured
The Results report that TMAO increased after surgery, with samples collected both 1–2 weeks and one year later; the Discussion describes the increase as significant. However, the study measured TMAO in serum, not plasma, and reports metabolomic signal intensities rather than quantified plasma levels. (LLM, conf=0.87)
- Supportedcites [66] Hov, 2016, Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery, Metab. Syndr. Relat. Disord. source
The Results report that plasma TMAO more than doubled one year after bariatric surgery. The Discussion also reports a study finding elevated TMAO nine years after surgery, although that finding was limited to women who underwent Roux-en-Y gastric bypass. Together, these support the statement about higher levels at shorter and longer follow-up times. (LLM, conf=0.88)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
41 more claims · 13 with their cited sources checked
Create a free account to see all 100 claims and to verify the 86 references still open.
- It may state two separate claims as one. 48
- Probably not a substantial claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another example is trimethylamine-N-oxide (TMAO), a hepatic metabolite generated from gut-derived precursors such as choline and L-carnitine.156”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [156]
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597 · cited 2×
“However, the levels of TMAO return to normal after one month of the withdrawal of the antibiotics [7,52].”
BackgroundIntestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400 · cited 1×
“However, the levels of TMAO return to normal after one month of the withdrawal of the antibiotics [7,52].”
BackgroundInnate immunity and intestinal microbiota in the development of Type 1 diabetes
Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., Stonebraker, A. C., Hu, C., Wong, F. S., Szot, G. L., Bluestone, J. A., et al. (2008) · Nature · doi:10.1038/nature07336 · Cited by 1,921
Wang, Z., Roberts, A. B., Buffa, J. A., Levison, B. S., Zhu, W., Org, E., Gu, X., Huang, Y., Zamanian-Daryoush, M., Culley, M. K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.055 · Cited by 1,317
Tang, W. H. W., Wang, Z., Kennedy, D. J., Wu, Y., Buffa, J. A., Agatisa-Boyle, B., Li, X. S., Levison, B. S., & Hazen, S. L. (2015) · Circulation Research · doi:10.1161/circresaha.116.305360 · Cited by 1,223 · cited 1×
“However, there are also some studies suggesting that TMAO can contribute to the development of renal insufficiency [50] and/or serve as a predictor of glomerular injury [51].”
BackgroundDumas, M.-E., Barton, R. H., Toye, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601056103 · Cited by 1,042
Cited by
Items 501–600 of 631
Melnychuk, I. O., Sharayeva, M. L., Kramarova, V. N., & Vh, L. (2023) · Pathologia · doi:10.14739/2310-1237.2022.3.263564 · Cited by 2
Polycentric binding in complexes of trimethylamine- N -oxide with dihalogens
Zarechnaya, O. M., Анисимов, А. А., Belov, E. Y., Burakov, N. I., Kanibolotsky, A. L., & Mikhailov, V. A. (2021) · RSC Advances · doi:10.1039/d0ra08165e · Cited by 2
Targeting the gut microbiome in coronary artery disease
Suzuki, T., Salzano, A., & Israr, M. Z. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.02.017 · Cited by 2
ON THE BIOLOGICAL ROLE OF CHOLINE IN HUMAN AND HIGHER ANIMAL ORGANISMS (A LITERATURE REVIEW)
Bekker, R. A., Bykov, Y. V., & Bykova, A. Y. (2021) · Siberian Journal of Life Sciences and Agriculture · doi:10.12731/2658-6649-2021-13-5-76-103 · Cited by 2
Snouper, A., Kasabri, V. N., Bulatova, N., Suyagh, M. F., Sadder, M. T., Shnewer, K., & Yousef, I. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01088-x · Cited by 3
Dailey, A., Solano-Aguilar, G. I., Urban, J. F., & Couch, R. D. (2023) · Metabolites · doi:10.3390/metabo13030358 · Cited by 2
Updates in the Medical and Nutritional Management of Short Gut Syndrome
Mathews, S. N., & Ravella, S. (2023) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-023-00419-z · Cited by 2
Cruz, B. O. D., Coutinho‐Wolino, K. S., Cardozo, L., Pereira, A. D., Mesquita, C. T., Stenvinkel, P., Bergman, P., Mafra, D., & Stockler‐Pinto, M. B. (2024) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20230113 · Cited by 4
Functional Role of Prebiotic Supplement in Brain Signalling
Rajamma, S. S., Krishnaswami, V., & Kandasamy, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-1626-6_9 · Cited by 2
Urinary Microbiota and Serum Metabolite Analysis in Patients with Diabetic Kidney DiseasePreprint
Yan, Y., Li, S., Ma, C., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4182276 · Cited by 2
Andreu‐Sánchez, S., Ahmad, S., Kurilshikov, A., Beekman, M., Ghanbari, M., van Faassen, M. H. J. R., van den Munckhof, I., Steur, M., Harms, A. C., Hankemeier, T., et al. (2022) · medRxiv · doi:10.1101/2022.09.01.22279510 · Cited by 2
Wang, X., Li, Z., Zhang, L., Guan, H., Li, D., Mo, Y., Wang, D., Nie, X., & Yao, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-3849756/v1 · Cited by 3
Singhal, S., & Rani, V. (2023) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/0118715257270512231013064533 · Cited by 1
Association between oral nutrition and inflammation after intestinal transplantation
Ravella, S. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.110809 · Cited by 1
Zhang, Y., He, Q., Cong, X., Qiu, H., & Hua, C. (2025) · Mediators of Inflammation · doi:10.1155/mi/9487093 · Cited by 1
Concentrations of uremic bacterial metabolites in patients with post-COVID-19 syndrome
Brigo, N., Mayr, W., Taenzer, M., Löffler‐Ragg, J., Schroll, A., Engl, S., Schütz, B., Rappl, P., Heine, T., Weiß, G., et al. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1582972 · Cited by 1
The role of the gut microbiome in cardiovascular disease
Świątko, M., Sosnowski, P., Rybak, J., Grzebyk, M., Tokarska, A., Arnista, A., Gawrońska, K., Waszczuk, A., Kołodziejczyk, A., & Łapiński, P. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.82.60447 · Cited by 1
Xing, Z., Xie, M.-M., Wang, H., Cui, Q., & Wang, X.-B. (2025) · Human Reproduction Open · doi:10.1093/hropen/hoaf045 · Cited by 1
Zhang, H., Wu, Y., Li, Y., Xue, Y., Jiao, Y., Sun, R., Ma, Y., Kulyar, M. F., Li, M., Xu, H., et al. (2025) · The FASEB Journal · doi:10.1096/fj.202501290rr · Cited by 1
Li, J., Peng, J., Yu, X. L., Zhou, S., Xu, B., Zou, H., Guo, F., Zhang, Y., Kou, M., Lin, H., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120852 · Cited by 1
Janus-faced role of anti-infective drugs: a revisit through the lens of vascular ageing
Silumbwe, C. W., Mulumba, J., Dharmarajan, S. K., Chennuru, A., Siame, L., & Mazyamuna, K. (2026) · Exploration of Drug Science · doi:10.37349/eds.2026.1008143 · Cited by 1
Gupta, D. K., & Kumar, R. (2026) · Cureus · doi:10.7759/cureus.103206 · Cited by 4
Su, R., Huang, C., Jing, Z., Qiu, S., Shao, L., Jiao, T., Wang, H., & Li, H. (2026) · Future Science OA · doi:10.1080/20565623.2026.2629346 · Cited by 1
Qian, S., Shi, Y., Li, J., Zhao, H., Ye, X., & Li, W. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05833-9 · Cited by 1
Dysbiosis and immunothrombosis – How platelets and the gut microbiome interact
Gurumurthy, G., Gurumurthy, J., Gurumurthy, S., Reynolds, L., & Thachil, J. V. (2026) · Blood Reviews · doi:10.1016/j.blre.2026.101395 · Cited by 2
Li, J., Chen, Y., Li, Z., Liu, G., Jiang, H., Fang, J., & Ding, S. (2026) · Food Frontiers · doi:10.1002/fft2.70287 · Cited by 1
Klisic, A. N., Tomašević, R., Đjurašković, S., Mercantepe, F., & Ninić, A. (2026) · Archives of Medical Science · doi:10.5114/aoms/219846 · Cited by 7
The gut microbiome and colorectal cancer
Dietz, M. A., Subramanian, S., & Staley, C. M. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00332-25 · Cited by 1
The gut–heart axis in cardio-oncology
Chan, N. S. L., Cross, C., Bowen, J., Prestidge, C. A., Ryan, F. J., Dorraki, M., Liyanage, S., Sharma, S., Pathy, R., Bursill, C. A., et al. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag146 · Cited by 1
Gut metabolites: key factors in the cross-talk between the gut microbiota and tumor immunotherapy
Zeng, L., Ren, Y., Huang, H., Wang, Q., Li, H., Song, J., He, F., & Li, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1882542 · Cited by 1
Gut microbiota interaction in host lipid metabolism
Golonka, R. M., Abokor, A. A., Ntambi, J. M., & Vijay–Kumar, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00016-6 · Cited by 3
Pella, D., Fedačko, J., Pella, D., Vargová, V., Mojto, V., Singh, R. B., & Smail, M. M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819815-5.00021-5 · Cited by 2
Brown, B., Almansouri, B. E., Heck, D. E., & Kim, H. D. (2021) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2021.17.3.0323 · Cited by 1
Contractile effect of trimethylamine and trimethylamine‐n‐oxide on isolated human umbilical arteries
Ongun, M. C., Örgül, G., Çelık, Ç., & Barışkaner, H. (2023) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15656 · Cited by 3
Yue, Y., Cui, H.-B., Chu, Y.-J., & Zheng, G.-L. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s431435 · Cited by 1
Yao, Y., Wang, X., Li, D., Chen, S., Li, C., Guan, H., Wang, D., & Nie, X. (2024) · Aging · doi:10.18632/aging.205657 · Cited by 1
Association between gut microbiota and thyroid dysfunction
Алексеевич, Т. А., Александровна, М. О., Олеговна, Щ. А., Martirosian, N. S., Валерьевна, Г. Е., Кузина, И. А., Эдуардовна, Т. М., Valeeva, F. V., & Petunina, N. A. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-073 · Cited by 1
Zawieja, E. E., Drabińska, N., Jeleń, H. H., et al. (2024) · Nutrition Research · doi:10.1016/j.nutres.2024.05.003 · Cited by 1
Evaluation of Trimethylamine N-Oxide (TMAO) Levels in Blunt Thoracic Trauma: An Experimental Study
Şengül, F., Akyürek, F., Öztürk, B., Vatansev, H., Bayır, A., Kara, H., & Körez, M. K. (2024) · Genel Tıp Dergisi · doi:10.54005/geneltip.1407693 · Cited by 1
Gut Microbiome Metabolites and the Intestinal Homeostasis
Metwally, H., & Kishimoto, T. (2024) · Journal of Clinical Research and Reports · doi:10.31579/2690-1919/371 · Cited by 3
Verheul, E. A. H., Ouwerkerk, J. J. J., Dijkink, S., Krijnen, P., Verhoeven, A., Giera, M. A., Yeh, D. D., & Schipper, I. B. (2024) · Topics in Clinical Nutrition · doi:10.1097/tin.0000000000000350 · Cited by 2
Gawalko, M. M., Jespersen, T., Dobrev, D., & Linz, D. (2020) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2020.100581 · Cited by 2
Subclinical markers of cardiometabolic risk in obese children and adolescents
Самойлова, Ю. Г., Ворожцова, И. Н., Oleynik, O. A., Diraeva, N., & Denisov, N. S. (2020) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2020-35-3-32-37 · Cited by 1
Link between gut microbiome and cardiometabolic diseases
Farooqui, T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821039-0.00013-7 · Cited by 2
Еременко, И. И. (2021) · Естественные и Технические Науки · doi:10.37882/2223-2966.2021.02.11 · Cited by 1
Nergiz‐Unal, R., & Gönen, B. (2021) · Akdeniz Medical Journal · doi:10.53394/akd.982129 · Cited by 2
The Link Between Gut Microbiota and Autoimmune Diseases
Goyal, D., Dey, M., & Singh, R. K. (2022) · Springer eBooks · doi:10.1007/978-981-19-1946-6_3 · Cited by 1
Kim, S.-J., Bale, S., Wan, Q., Gudjonsson, J. E., Hazen, S. L., Harms, P. W., Tsou, P., Khanna, D., Tsoi, L. C., Gupta, N., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3912949 · Cited by 1
Janeiro, M. H., Puerta, E., Lanz, M., Milagro, F. I., Ramírez, M. J., & Solas, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.17.469001 · Cited by 1
Self-citationFechtner, S., Allen, B. E., Chriswell, M. E., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3297018/v1 · Cited by 1
Smith, C. B., Gao, A. Y., Bravo, P., & Alam, A. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.10.588895 · Cited by 2
Ji, W., Zhang, B., Liu, J., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5191104 · Cited by 1
The Gastrointestinal Microbiome in Chronic Renal Diseases
Bryniarski, M. A., Hoffman, S. E. M., & Yacoub, R. (2020) · Current Oral Health Reports · doi:10.1007/s40496-020-00258-2
Li-na, M., Jian-peng, D., Guo, M. H., Zhu-hong, C., Qu, H., & Da-zhuo, S. (2021) · medRxiv · doi:10.1101/2021.05.04.21256606
Macpherson, M. E. (2020) · NORA - Norwegian Open Research Archives
Jumpstarting metabolomics and the next generation of clinically useful gut-brain microbiome research
Severance, E. G. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.01.019
Microbiota Modulation to Reduce Cardiovascular Risk in HIV Patients: A Systematic ReviewPreprint
Villoslada-Blanco, P., Pérez‐Matute, P., & Oteo José, A. (2021) · Research Square · doi:10.21203/rs.3.rs-172182/v1
Changes in the Urinary Metabolites in Losartan-Treated Spontaneously Hypertensive Rats
Azis, N. A., Kamal, M. S. A., Radjeni, Z., Mediani, A., & Agarwal, R. (2021) · Journal of Clinical and Health Sciences · doi:10.24191/jchs.v6i1.12442
Assay developments for detection of biological analytes
Tan, J. (2019) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/143757
Gut Microbiome and Liver Cancer
McVey, J. C., Zhang, Q., Greten, T. F., & Ma, C. (2021) · Physiology in health and disease · doi:10.1007/978-3-030-67951-4_7
Galena, A. E. (2021) · University of North Florida Digital Commons (University of North Florida)
Gut microbiota and their effects on atherosclerosis, platelet function, and hypertension
Duttaroy, A. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822405-2.00022-0 · Cited by 1
Mikrobiom und Stoffwechsel beim polyzystischen Ovarialsyndrom (PCOS)
Heizmann, W. R., & Keck, C. (2021) · Der Gynäkologe · doi:10.1007/s00129-021-04829-x
Plant-Based Diets in the Prevention and Treatment of Cardiovascular Disease
Vasudevan, R. S., Rosander, A. M., Pazargadi, A., & Wilkinson, M. J. (2021) · Contemporary cardiology · doi:10.1007/978-3-030-78177-4_6
Самойлова, Ю. Г., Олейник, О., Sagan, E. V., & Денисов, Н. (2021) · Modern Issues of Biochemistry, Genetics and Biotechnology · doi:10.33184/spbgb-2021-09-21.40
Application of metabolomics to assess the intestinal response to dietary supplementation
Borzouie, S., Rathgeber, B. M., & MacLaren, L. A. (2022) · CABI Reviews · doi:10.1079/cabireviews202217004
Yang, Y. H., Li, S., Ma, C., Cai, W., Dai, W., Zhang, X., Yin, L., Tang, D., Liu, F., & Dai, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1543293/v1
Research Progress of Atherosclerosis-Related Youth Stroke
(2022) · Journal of Addiction Research · doi:10.33140/jar.06.01.10
Metabolic Abnormalities in Hypertensive patients and their Risk Factors
Ashraf, M. I., Rana, S., Makhtar, M. S., Afzal, A., Suhail, B., Mukhtar, S., Fatima, J., Shahzad, A., & Shaukat, A. (2021) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs211571494
Obesidad y enfermedad hepática grasa no alcohólica en Pediatría.
Soto, G. F. F., de Fernández, C. A., Valero, N. J., Ortiz, E. V. T., Raza, C., Valencia, P., Martínez, A., & Lopez, J. (2019) · Enfermería Investiga · doi:10.29033/enfi.v4i3.590 · Cited by 1
Focusing on the metabolic changes caused by the COVID-19 disease. A Metabolomic approach using urinePreprint
Marhuenda-Egea, F. C., Narro-Serrano, J., Shalabi-Benavent, M. J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1753062/v1
Trimethylamine N-Oxide (TMAO) as a Biomarker: Features and Applications [to nutrition]
Gabbianelli, R., & Bordoni, L. (2022) · Biomarkers in disease · doi:10.1007/978-3-030-81304-8_2-1 · Cited by 1
Gut microbiota in human health: insights and discussion on the role of probiotics
Patwari, S. (2022) · International Journal of Scientific Reports · doi:10.18203/issn.2454-2156.intjscirep20223040 · Cited by 1
Gut Microbiome and Obesity: Connecting Link
Mishra, J., Amin, K., Kuang, L., & Kumar, N. (2022) · Springer eBooks · doi:10.1007/978-981-19-3979-2_4 · Cited by 1
Trimethylamine N-Oxide (TMAO) as a Biomarker: Features and Applications [to nutrition]
Gabbianelli, R., & Bordoni, L. (2022) · Biomarkers in disease · doi:10.1007/978-3-031-07389-2_2
Castro, R., Kalecký, K., Huang, N., Petersen, K. S., Singh, V., Ross, A., Neuberger, T., & Bottiglieri, T. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.07.527515
Role of Human Microbiome in Cardiovascular Disease: Therapeutic Potential and Challenges
Maran, S., Yeo, W. W. Y., Lai, K., & Lim, S. E. (2023) · Springer eBooks · doi:10.1007/978-981-99-1463-0_13
Progress on the Role of “Gutbacteria-Gut-Liver Axis” in Non-Alcoholic Fatty Liver Disease
陈, 孟. (2023) · Medical Diagnosis · doi:10.12677/md.2023.132038 · Cited by 1
The Emerging Role of Microbiome in Cardiovascular Diseases
Shehata, E., & Day-Walsh, P. E. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815165012123010008
Козловський, В. О., & Соловйов, А. І. (2023) · Pharmacology and Drug Toxicology · doi:10.33250/17.02.090
Gut Microbiota and Cardiovascular Disease
Negm, S. H. (2023) · Wiley eBooks · doi:10.1002/9781119904786.ch9 · Cited by 3
ผลของการบริโภคฟักข้าวต่อระดับไตรเมทิลามีนเอ็นออกไซด์ในเลือดและการเกิดโรคหัวใจในหนูไตวายเรื้อรัง
เข้มแข็ง, ภ., ดิษยบุตร, ฐ., ช่วยเพ็ญ, ณ., & ทรัพย์วโรบล, ส. (2022) · Chula Digiverse · doi:10.58837/chula.the.2022.559
THE ROLE OF THE INTESTINAL MICROBIOTA METABOLITE TMAO IN THE PATHOGENESIS OF VARIOUS DISEASES
Samoilova-Bedych, N., Laryushina, Е. М., Marchenko, A., & Сейсенбекова, А. К. (2024) · Farmaciâ Kazahstana · doi:10.53511/pharmkaz.2024.25.65.015 · Cited by 1
Exploring the Role of Gut Microbiota in Metabolic Diseases Based on the Gut-Liver Axis
蒋, 晓. (2024) · Pharmacy Information · doi:10.12677/pi.2024.133019
Nogal, A., Louca, P., Valdes, A. M., Padmanabhan, S., & Menni, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822951-4.00007-2
Unveiling the microbial metabolites in ruminant milk for medicinal purposes
Jia, Q., Yang, T., Chang, F., Zhang, Q., Liang, J., Liao, X., & Shi, H. (2024) · Food Frontiers · doi:10.1002/fft2.471 · Cited by 1
Melnychuk, I. O., & Kramarova, V. N. (2024) · Medicine Today and Tomorrow · doi:10.35339/msz.2024.93.2.mkr
The Role of Gut Microbiota in Psoriasis: Current Knowledge and Emerging Therapeutic Interventions
Memariani, H., & Memariani, M. (2024) · International Journal of Enteric Pathogens · doi:10.34172/ijep.5636
The Role of Early Child Nutrition in Pulmonary Hypertension—A Narrative Review
Luca, A.-C., Stoica, C. I., Diaconescu, C., Țarcă, E., Roşu, S. T., Butnariu, L. I., Stana, B. A., Gafton, B., Curici, A., Roşu, E. V., et al. (2024) · Children · doi:10.3390/children11111307
Hefni, M. E., & Witthöft, C. M. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5054837
Research Progress on the Relationship between Gut Microbiome and Parkinson’s Disease
力比奴尔·塞地尔丁, 克. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14123217
李, 雪. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.42140
Saikia, G., Shen, X., Liu, Y., Yang, K., Wu, H., Lu, L.-P., Butler, J. L., Johnson, C., Lou, G., Wu, S., et al. (2025) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2024-001111
Dubey, A. K., & Singh, S. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-6246-3_4
Investigation of Plasma TMAO Levels in Children and Adolescents with ADHD: A Cross-Sectional Study
Güleç, A., Türkoğlu, S., Kocabaş, R., & Tezcan, M. E. (2025) · Genel Tıp Dergisi · doi:10.54005/geneltip.1592267
Tan, X., Zhuang, J., Xing, Y., Qiu, S., Guo, L., Gao, C., Li, G., Liu, Z., Song, Y., & Hu, Y. (2025) · Research Square · doi:10.21203/rs.3.rs-7058350/v1
How the Microbiome Drives Cardiovascular Disease
Ho, K. J., Vs, J., Abualhuda, A., & Wang, B. (2025) · Surgical Clinics of North America · doi:10.1016/j.suc.2025.07.001
Metadata
- Authors
- Janeiro, M., Ramírez, M., Milagro, F., Martínez, J., & Solas, M.
- Affiliations
- Navarre Institute of Health Research (ES)
- Instituto de Salud Carlos III (ES)
- Corresponding author
- Solas, Maite
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2018-10-01
- Volume
- 10
- Issue
- 10
- Pages
- 1398
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC6213249
- OpenAlex
- W2892844483
- Semantic Scholar
- adc60d5222b7111574299ed6bab9c7ab4f1f418a
- Cited by
- 631
- References
- 106
- Citations by year
- 2026: 46 · 2025: 79 · 2024: 100 · 2023: 90 · 2022: 112 · 2021: 102 · 2020: 71 · 2019: 31
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, other-oa)
- Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Gobierno de Navarra (PI035)
- Instituto de Salud Carlos III
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Polyamine Metabolism and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- trimethylamine N-oxide, gut microbiota, cardiovascular disease, neurological disorders, biomarkers, therapeutic target, flavin-containing monooxygenase, choline metabolism, food sources, inflammation, broad-spectrum antibiotics, gut-brain axis
- MeSH terms
- Cardiovascular Diseases, Humans, Methylamines, Nervous System Diseases, Biomarkers, Inflammation Mediators, Metabolic Networks and Pathways, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.